Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims: Higher doses of the glucagon‐like peptide‐1 agonist semaglutide and, more recently, tirzepatide, a dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 agonist showed a significant reduction in body weight in patients with type 2 diabetes mellitus. However, their comparative value for money for this indication is unclear. Therefore, we aimed to establish which provides better value for money. Materials and Methods: We calculated the cost needed to treat to achieve a 1% reduction in body weight using high‐dose tirzepatide (15 mg) versus semaglutide (2.4 mg). The body weight reductions were extracted from published results of SURMOUNT‐1 and STEP 1 trials, respectively. In addition, we performed a scenario analysis to mitigate the primary differences between the two study populations. Drug costs were based on US GoodRx prices as of October 2022. Results: Using tirzepatide resulted in a weight loss of 17.8% (95% CI: 16.3%‐19.3%) compared with 12.4% (95% CI: 11.5%‐13.4%) for semaglutide. The total cost of 72 weeks of tirzepatide was estimated at $17 527 compared with $22 878 for 68 weeks of semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908‐$1075) compared with $1845 (95% CI: $1707‐$1989) with semaglutide. Scenario analysis confirmed these findings. Conclusions: Tirzepatide provides better value for money than semaglutide for weight reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“High doses of the glucagon-like peptide-1 agonist (GLP-1RA) semaglutide and the dual glucose-dependent insulinotropic polypeptide and GLP-1RA tirzepatide have significantly reduced weight in patients with T2DM in STEP 1 and SURMOUNT-1 trials, with a follow-up of 68 and 72 weeks, respectively.(10,11) Although obesity-a…”
BackgroundTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“High doses of the glucagon-like peptide-1 agonist (GLP-1RA) semaglutide and the dual glucose-dependent insulinotropic polypeptide and GLP-1RA tirzepatide have significantly reduced weight in patients with T2DM in STEP 1 and SURMOUNT-1 trials, with a follow-up of 68 and 72 weeks, respectively.(10,11) Although obesity-a…”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · cited 2×
“mainstay of management is lifestyle modification, but long-term outcomes for sustained weight loss are poor.(1,2,8,9) Novel pharmacological treatments have recently been approved as adjunct therapies for weight reduction.”
BackgroundLong-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“mainstay of management is lifestyle modification, but long-term outcomes for sustained weight loss are poor.(1,2,8,9) Novel pharmacological treatments have recently been approved as adjunct therapies for weight reduction.”
BackgroundNeeland, I. J., Poirier, P., & Després, J.-P. (2018) · Circulation · doi:10.1161/circulationaha.117.029617 · Cited by 881
Li, G., Zhang, P., Wang, J., An, Y., Gong, Q., Gregg, E. W., Yang, W., Zhang, B., Shuai, Y., Hong, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70057-9 · Cited by 684
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45 · cited 1×
“A recent study attempted to calculate quality-adjusted life years indirectly for glucagon-like peptide-1 agonists based on existing data and found that semaglutide was the most costeffective of the drugs tested.(16) Tirzepatide is first in a new drug class that also induces clinically relevant weight reduction.”
BackgroundUse of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021) · Obesity Facts · doi:10.1159/000518325 · Cited by 41
Trenson, L., Trenson, S., van Nes, F., Moyson, C., Lannoo, M., Deleus, E., Meulemans, A., Matthys, C., Mertens, A., Van der Schueren, B., et al. (2022) · Obesity Facts · doi:10.1159/000520217 · Cited by 34 · cited 1×
“Recent real-world data studies have replicated the findings of previous GLP-1RA trials, with significant weight loss achieved, and the weight loss is similar across different doses.(17,18) This reinforces the importance of GLP-1RAs as an effective treatment for weight loss.”
Result
Cited by
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Brain Sciences · doi:10.3390/brainsci13111503 · Cited by 104
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Berning, P., Adhikari, R., Schroer, A. E., Jelwan, Y. A., Razavi, A. C., Blaha, M. J., & Dzaye, O. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57232 · Cited by 78
Chiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Pharmaceuticals · doi:10.3390/ph16070994 · Cited by 78
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A. (2025) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6231 · Cited by 19
Metadata
- Authors
- Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-12-27
- Volume
- 25
- Issue
- 4
- Pages
- 961-964
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4311206282
- Cited by
- 40
- References
- 12
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.